Resources and Tools to Accelerate Oligonucleotide Therapeutics to Market

Oligonucleotide therapeutics are short DNA or RNA molecules that modulate the expression of target RNA for the treatment of diseases. The success of mRNA-based COVID-19 vaccines has brought renewed interest to other nucleic acid drugs, and the oligo therapeutics market is expected to grow by 25–30% in the next five years with over 1,000 oligonucleotide molecules currently in the pipeline.

Download this eBook to learn more about oligonucleotide:

Trends and insights
Starting materials
Profiling and impurity control
Identification and quantitation

I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com.

I acknowledge Thermo Fisher Scientific (including its affiliates) will process my Personal Information according to its Privacy Policy, which includes information about my rights

Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This content is copyright protected. Any public or private use of this content is subject to prevailing copyright laws. Please contact Technology Networks for permission requests.

Resources and Tools To Accelerate Oligonucleotide Therapeutics to Market